职业经历

Dr. Lodge 是一名细胞生物学家，在学术研究领域具有广泛的经验，初期从事制药及干细胞疗法监管事务。博士和博士后就读阶段，他主要研究神经系统发育过程中肌动蛋白细胞骨架和细胞黏附分子对轴突导向的作用。Dr. Lodge 于2001年加入葛兰素史克 (GlaxoSmithKline) 公司，领导神经变性疾病和精神疾病的目标识别和确认工作，以及干细胞相关的药物研发战略的开发。2009年至2011年间，Dr Lodge任伦敦大学学院 (University College London) 干细胞疗法项目负责人，负责根据最新颁布的高级治疗要用产品(ATMPs)指令申请相关证照的工作。他具有广泛的细胞生物、分子生物和蛋白质生化技术等方面的专业技能，在国际同行评审期刊上发表过多篇第一作者文章，对于多种临床前及临床规范性文件的写作经验丰富。Dr. Lodge 目前从事基于细胞的药物研究、ATMP监管事务以及学术写作(包括web开发)方面的咨询工作，从2008年起开始为 Edanz Group 工作。

Dr Lodge is a cell biologist with wide-ranging experience in academic research, early stage drug discovery, and stem cell therapy regulatory affairs. For his PhD and postdoctoral work, Dr Lodge studied the roles of the actin cytoskeleton and cell adhesion molecules in axon guidance during nervous system development. Dr Lodge joined GlaxoSmithKline in 2001, where he held research and programme leadership roles within target validation initiatives for neurodegenerative and psychiatric diseases. He was also involved in developing drug discovery strategies involving stem cells. From 2009 to 2011, Dr Lodge was Programme Manager for a stem cell therapy unit at University College London, where he was responsible for the unit obtaining the necessary licenses required by the recently introduced Advanced Therapy Medicinal Products (ATMPs) directive. His technical expertise covers a broad spectrum of cell biology, molecular biology and protein biochemistry techniques, including their application to drug discovery assay development. Dr Lodge has published several first author publications in international peer-reviewed journals, and he is experienced in writing a variety of pre-clinical and clinical regulatory documents. Dr Lodge currently offers consulting services in cell-based drug discovery, ATMP regulatory affairs, and scientific writing (including web development). He began editing for the Edanz Group in 2008.